Darunavir/ritonavir and rosuvastatin
26 August 2010. Related: Conference reports, PK and drug interactions.
PK and drug interactions
Darunavir/ritonavir and hepatic impairment
26 August 2010. Related: PK and drug interactions.
Case report lack of PK interaction between bosentan and nevirapine
26 August 2010. Related: PK and drug interactions.
Pharmacokinetics of once daily darunavir/ritonavir and efavirenz
26 August 2010. Related: PK and drug interactions.
11th International Workshop on Clinical Pharmacology of HIV Therapy, 7-9 April, 2010, Sorrento, Italy
1 June 2010. Related: Conference reports, PK and drug interactions.
Atazanavir absorption maximised with food
1 June 2010. Related: Conference reports, PK and drug interactions.
Methadone levels reduced moderately by rilpivirine
1 June 2010. Related: Conference reports, PK and drug interactions.
Maraviroc 150mg once-daily achieves target concentrations with atazanavir/ritonavir
1 June 2010. Related: Conference reports, PK and drug interactions.
Raltegravir and unboosted atazanavir
1 June 2010. Related: Conference reports, PK and drug interactions.
Raltegravir dose adjustment not required for patients on dialysis
1 June 2010. Related: Conference reports, PK and drug interactions.
Raltegravir and darunavir pharmacokinetics in liver disease
1 June 2010. Related: Conference reports, PK and drug interactions.
Tenofovir may require closer renal monitoring in older patients
1 June 2010. Related: Conference reports, PK and drug interactions, Injecting drug users.
Effect of age on atazanavir, darunavir, raltegravir and etravirine
1 June 2010. Related: Conference reports, PK and drug interactions.
Proposed approach to measuring TDM for raltegravir
1 June 2010. Related: Conference reports, PK and drug interactions.
Increased bilirubin levels when atazanavir is dosed twice-daily
1 June 2010. Related: Conference reports, PK and drug interactions.
Poor bioequivalence with crushed and dissolved tablets
1 June 2010. Related: Conference reports, Paediatric care, PK and drug interactions.
No clinically relevant interactions between TMC278 and oral contraceptives (norethindrone plus ethinylestradiol)
21 February 2010. Related: Conference reports, Women's health, PK and drug interactions.
Pilot PK study of two generic paediatric formulations of lopinavir/ritonavir vs originator products
21 February 2010. Related: Conference reports, Paediatric care, PK and drug interactions.
Other selected PK and drug interaction summaries from EACS
21 February 2010. Related: Conference reports, PK and drug interactions.
No interaction between tipranavir/ritonavir and efavirenz
8 February 2010. Related: PK and drug interactions.
Significant interactions between tipranavir/ritonavir and statins
8 February 2010. Related: PK and drug interactions.
Summary of interactions between vivriviroc and other ARVs
8 February 2010. Related: PK and drug interactions.
Significant interaction between atazanavir/ritonavir and the antipsychotic drug quetiapine
8 February 2010. Related: PK and drug interactions.
Alcohol and marijuana may reduce drug levels of atazanavir and efavirenz
31 December 2009. Related: Conference reports, PK and drug interactions.
Other drug interaction studies at ICAAC
31 December 2009. Related: Conference reports, PK and drug interactions.
Reduced etravirine levels after direct switch from efavirenz
30 December 2009. Related: PK and drug interactions.
Gemfibrozil significantly reduced by lopinavir/r
30 December 2009. Related: PK and drug interactions.
Raltegravir trough levels reduced by etravirine may require use of TDM
2 October 2009. Related: PK and drug interactions.
Lopinavir/r affects PK exposure of some antimalarial drugs
2 October 2009. Related: PK and drug interactions.
Darunavir/r increases exposure to nevirapine
2 October 2009. Related: PK and drug interactions.
Interaction between Ginkgo biloba and efavirenz
2 October 2009. Related: PK and drug interactions.
Use of raltegravir in HIV-positive transplant recipients
2 October 2009. Related: PK and drug interactions.
Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination
23 August 2009. Related: Conference reports, PK and drug interactions.
Interactions between ARVs and antimalarials atovaquone and proguanil
23 August 2009. Related: Conference reports, PK and drug interactions.
Efavirenz lowers levels of darunavir given as 900/100mg once daily with ritonavir
3 June 2009. Related: Conference reports, PK and drug interactions.
Potential interactions between antiviral treatment for swine flu (H1N1) and anti-HIV therapy
2 June 2009. Related: PK and drug interactions.
Case reports of significant interactions between etravirine and raltegravir
2 June 2009. Related: PK and drug interactions.
Effect of tenofovir on abacavir phosphorylation
20 April 2009. Related: Conference reports, PK and drug interactions.
PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy
20 April 2009. Related: Conference reports, PK and drug interactions.
Effects of omeprazole on plasma levels of raltegravir
20 April 2009. Related: PK and drug interactions.
Interaction study of ketoconazole and ritonavir-boosted saquinavir
20 April 2009. Related: PK and drug interactions.
Tipranavir/ritonavir interactions with clarithromycin, fluconazole and rifabutin
20 April 2009. Related: PK and drug interactions.
Antiretroviral and statin drug-drug interactions
20 April 2009. Related: PK and drug interactions.
Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir
9 February 2009. Related: PK and drug interactions.
Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir
9 February 2009. Related: PK and drug interactions.
Drug interactions with integrase inhibitors
9 February 2009. Related: PK and drug interactions.
Drug interactions between efavirenz and itraconazole
9 February 2009. Related: PK and drug interactions.
Effect on tacrolimus when switching from nelfinavir to fosamprenavir
9 February 2009. Related: PK and drug interactions.
Drug interaction studies with approved drugs
26 December 2008. Related: Conference reports, PK and drug interactions.
Key papers on methadone and ritonavir
26 December 2008. Related: PK and drug interactions.
Drug interaction reports from Liverpool University website
30 October 2008. Related: PK and drug interactions.
Darunavir/ritonavir interaction with clarithromycin warrants caution
1 February 2008. Related: PK and drug interactions.
Updated and new resources on HIV drug interactions
1 February 2008. Related: PK and drug interactions.
Drug interaction studies presented at EACS
1 December 2007. Related: Conference reports, PK and drug interactions, Basic science and immunology.
New drug interaction summary tables: maraviroc, integrase inhibitors, etravirine, hormonal contraceptives
1 December 2007. Related: PK and drug interactions.
Acid reducing agents and protese inhibitors
1 December 2007. Related: PK and drug interactions.
Atazanavir, with or without ritonavir, may increase buprenorphine and buprenorphine metabolites, requiring dose adjustment
1 December 2007. Related: PK and drug interactions.
T-20 increases tipranavir levels but not hepatotoxicity
1 December 2007. Related: PK and drug interactions.
The effect of lopinavir/r on the renal clearance of tenofovir
1 December 2007. Related: PK and drug interactions.
Drug-drug interactions
3 July 2007. Related: Conference reports, PK and drug interactions.
Drug interactions and pharmacokinetic studies: CROI 2007
4 April 2007. Related: Conference reports, PK and drug interactions.
Drug interactions with darunavir (TMC-114)
6 December 2006. Related: Conference reports, PK and drug interactions.
Drug interactions with etravirine (TMC-125)
6 December 2006. Related: Conference reports, PK and drug interactions.
Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives
7 October 2006. Related: Conference reports, PK and drug interactions.
Relationship between nevirapine concentrations and virological failure in a clinical setting
11 June 2006. Related: Conference reports, PK and drug interactions.